Retina

Dr Anand Vinekar descibes how tele-ophthalmology models for ROP can be used in developing countries, using a successful Indian programme as a case study.

A review of the role and efficacy of anti-VEGF therapy in macular disease

Cataract surgery in patients with pre-existing AMD: Risks and Benefits

Canon Europe, revealed its new CX-1, a world first in retinal imaging technology for the first time at this year's ESCRS Congress.

A new study conducted by researchers at the University of Aberdeen, Scotland, has found that the brain predicts the consequences of eye movement even before the eyes take in a new scene.

High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy (DR), according to researchers at the Medical College of Georgia (MCG) School of Medicine, USA.

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

Evaluation of a new value-based treatment approach for wet AMD.

In the second of a two-part article Drs Lombardi and Belilli present the results of a patient suffering with a wet maculopathy affecting both eyes.

Partial sections of vision were recently restored to a blind woman's retina through the use of gene therapy.

This month's Ophthalmology, the journal of the American Academy of Ophthalmology, reports on use of bevacizumab (Avastin), to benefit diabetic patients with macular oedema as well as people who develop cystoid macular oedema after cataract surgery.

The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease.

Spanish researchers have used the induction of neuronal degeneration of intense light exposure in mice retina in an experimental model of retinitis pigmentosa.

Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables.

Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.

Stemedica Cell Technologies, Inc., (Stemedica),a manufacturer and developer of clinical grade allogeneic adult stem cell technology, has discovered a significant breakthrough in the use of human stem cells and stem cell factors for the potential treatment of degenerations of the retina and retinal pigmented epithelium.

Stem cell technology for AMD treatment

Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.

A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a team of researchers from the University of Kentucky.

A new suite of optical coherence tomography (OCT) software applications for the Cirrus HD-OCT has been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution.

Dr Jayakrishna Ambati, professor and vice chairman of Ophthalmology and Visual Sciences at the University of Kentucky, has been chosen to receive the 2010 Cogan Award from The Association for Research in Vision and Opthalmology (ARVO).

The twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study investigating the efficacy and safety of combining Visudyne (Novartis Pharma AG) and Lucentis (Novartis Pharma AG, Genentech Inc.) have been released and so far are showing no significant differences.

A genetic link between cats and humans for two forms of retinitis pigmentosa (RP) have been identified by a University of Missouri researcher.

Positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration (wet AMD) have been announced by QLT Inc.

Researchers at the University of Sydney have reported findings that support evidence of an association between retinal microvascular signs and stroke.

Stem cells, extracted from bone marrow can restore damaged retinal tissue through new cell generation, according to a recent discovery by researchers at the University of Louisville.

Diets low in trans-unsaturated fat and rich in omega-3 fatty acids and olive oil may reduce the risk of AMD, according to a study by Chong et al., published in The Archives of Ophthalmology.

Sutureless transconjunctival 20 g ppv is, according to this study, an ideal technique for all vitreoretinal surgeries.

New research indicates that patients with diabetic retinopathy (DR) should also be screened for obstructive sleep apnoea (OSA).

A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health. The RetmarkerDR is able to calculate and provide important ratios regarding Microaneurysm Turnover (formation and disappearance rates) which are key indicators of progression of retinal diseases like Diabetic Retinopathy.